Similarly, the mTOR inhibitor everolimus did not demonstrate a survival benefit in patients with advanced GC in the GRANITE-1 study [42], likely in part because inhibition of mTOR activates a feedback loop which upregulates PI3K activity, thereby attenuating the anti-tumour efficacy of mTOR inhibitors [43]. Here, MTOR is linked to gastric cancer.